 |
| Image created by Dr. Michael J. Miller |
T2 Biosystems announced that it plans to license its proprietary technology for the detection of sepsis-causing pathogens from whole blood.
In a statement, the Lexington, MA-based firm said that the licensing will expand its business model to generate nondilutive capital, develop a new revenue stream through royalties, and “accelerate the broad adoption of direct-from-whole-blood diagnostics to detect sepsis-causing pathogens and antibiotic resistance.”
The patented sample processing may be adapted to detection methods other than T2's Magnetic Resonance (T2MR) detection, such as fluorescence, potentially enabling other diagnostic platforms to integrate its technology to detect sepsis-causing pathogens and antibiotic resistance directly from whole blood without the need for a blood culture, according to the company.
The proprietary technology was used to develop the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel, which the company notes are the first U.S. Food and Drug Administration (FDA)-cleared diagnostics able to detect sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need for a positive blood culture, which can take from one to five days. The company received FDA clearance for its T2Candida Panel to be used for pediatric patients in September.
T2 recently had a patent upheld by the European Patent Office; BioMérieux and another undisclosed firm filed a challenge to the patent in May 2023. The patent covers a novel method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample, according to the firm.